Nanobiotix annual net income
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix Net Income Growth & History (NANO)
Nanobiotix's net income was −€24.0M for fiscal 2025.
View full Nanobiotix company overviewNanobiotix annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€24.0M | €44.2M | — |
| 2024 | 2024-12-31 | −€68.1M | −€28.4M | — |
| 2023 | 2023-12-31 | −€39.7M | €17.3M | — |
| 2022 | 2022-12-31 | −€57.0M | −€10.0M | — |
| 2021 | 2021-12-31 | −€47.0M | −€13.4M | — |
| 2020 | 2020-12-31 | −€33.6M | €17.3M | — |
| 2019 | 2019-12-31 | −€50.9M | −€20.6M | — |
| 2018 | 2018-12-31 | −€30.3M | — | — |
Nanobiotix net income trends
Over the last five fiscal years, Nanobiotix's net income increased from −€33.6M to −€24.0M, a change of €9.6M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nanobiotix source filings ↗Community posts
Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subse ...
